Chantix and cardiovascular risk: meta-analysis (CMAJ) - PulmCCM
Advertisement
Dec 262011
 

Singh et al report in a meta-analysis of 14 randomized trials (n=8,216) that varenicline was associated with an odds ratio of 1.72 for serious cardiovascular events compared to placebo. The absolute increased risk was 0.24% (a number needed to harm of 400, while varenicline has a number needed to treat of ~10 to get one quit smoker). The authors’ methodology is challenged by multiple credible online commenters, worth reading before throwing Chantix under the bus. CMAJ online July 4 2011.

Liked this post? Get a weekly email update (no spam, ever), and explore our library of pulmonary and critical care guidelines, practice updates and review articles.

PulmCCM is an independent publication, not affiliated with or endorsed by any other organization, society and/or journal referenced on the website.

Leave a Comment